A recent study has found that a widely used antibiotic, cefepime, could be linked to an increased risk of death. This drug, which is typically given via injection, is often used to treat various bacterial infections, including pneumonia, urinary tract infections, and skin infections. According to the Mayo Clinic, serious side effects might include confusion, decreased consciousness, or seizures, particularly among older adults and those with kidney issues.
The new research, published in JAMA Network Open, indicates that cefepime could correlate with higher all-cause mortality rates. The study examined 110 randomized clinical trials involving over 22,000 patients who were treated with either cefepime or other beta-lactam antibiotics, a category that includes penicillins and cephalosporins.
Patients in these trials included both adults and children suffering from febrile neutropenia—an acute condition characterized by fever and significantly reduced white blood cells—as well as pneumonia, severe infections, urinary tract infections, and meningitis.
From the trials reviewed, 778 deaths occurred among 11,726 patients (6.6%) who received cefepime, compared to 6.2% in those treated with alternative antibiotics. Researchers identified deaths occurring within approximately 30 days post-treatment to evaluate the outcomes.
Using a Bayesian meta-analysis, the study indicated a 94.4% likelihood that cefepime was linked to higher overall mortality compared to other beta-lactam antibiotics, a figure that rose to 98.6% when limited to 73 peer-reviewed trials. The risk appeared to be more pronounced in adults than children and was especially significant in patients with febrile neutropenia.
Despite these findings, cefepime continues to be a commonly prescribed broad-spectrum antibiotic for serious bacterial infections in hospitalized individuals, given its efficacy against a wide range of pathogens. The researchers did not recommend immediate withdrawal of the drug, but they emphasized the need for further investigation and clearer guidelines to understand its safety profile.
Several factors could potentially clarify the observed increased mortality associated with cefepime, but the researchers did not pinpoint a single cause. Possible reasons might include insufficient drug levels to effectively combat infections or neurotoxicity resulting from excessively high levels of the medication.
Establishing the appropriate dosing for cefepime can be tricky since higher dosages might enhance its antibacterial activity yet also raise the risk of toxic side effects. However, the study faced some limitations, such as the variability among clinical trials regarding design, patient diversity, dosing strategies, and comparison groups, with some studies dating back many years. Importantly, the analysis indicated an association rather than definitive proof that cefepime caused increased mortality.
Dr. Marc Siegel, a senior medical analyst, noted that the study highlights the necessity of revisiting and reassessing older research. He pointed out that febrile neutropenia itself poses a significant mortality risk, complicating the evaluation of whether cefepime is beneficial or detrimental in this context. A closer examination of the data suggests that both underdosing and overdosing could be more closely associated with adverse outcomes and increased mortality, which leads to the notion that ideal dosing is crucial. Siegel even proposed that artificial intelligence could play a role in determining accurate dosages and predicting outcomes.
